Cargando…

SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner

BACKGROUND: Pathological cardiac hypertrophy is regarded as a critical precursor and independent risk factor of heart failure, and its inhibition prevents the progression of heart failure. Switch‐associated protein 70 (SWAP70) is confirmed important in immunoregulation, cell maturation, and cell tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Qiaofeng, Hu, Fengjiao, Yu, Wenjun, Leng, Dewen, Li, Yang, Shi, Hongjie, Deng, Dawei, Ding, Kehan, Liang, Chuan, Liu, Jinping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122912/
https://www.ncbi.nlm.nih.gov/pubmed/36974751
http://dx.doi.org/10.1161/JAHA.122.028628
_version_ 1785029585472061440
author Qian, Qiaofeng
Hu, Fengjiao
Yu, Wenjun
Leng, Dewen
Li, Yang
Shi, Hongjie
Deng, Dawei
Ding, Kehan
Liang, Chuan
Liu, Jinping
author_facet Qian, Qiaofeng
Hu, Fengjiao
Yu, Wenjun
Leng, Dewen
Li, Yang
Shi, Hongjie
Deng, Dawei
Ding, Kehan
Liang, Chuan
Liu, Jinping
author_sort Qian, Qiaofeng
collection PubMed
description BACKGROUND: Pathological cardiac hypertrophy is regarded as a critical precursor and independent risk factor of heart failure, and its inhibition prevents the progression of heart failure. Switch‐associated protein 70 (SWAP70) is confirmed important in immunoregulation, cell maturation, and cell transformation. However, its role in pathological cardiac hypertrophy remains unclear. METHODS AND RESULTS: The effects of SWAP70 on pathological cardiac hypertrophy were investigated in Swap70 knockout mice and Swap70 overexpression/knockdown cardiomyocytes. Bioinformatic analysis combined with multiple molecular biological methodologies were adopted to elucidate the mechanisms underlying the effects of SWAP70 on pathological cardiac hypertrophy. Results showed that SWAP70 protein levels were significantly increased in failing human heart tissues, experimental transverse aortic constriction–induced mouse hypertrophic hearts, and phenylephrine‐stimulated isolated primary cardiomyocytes. Intriguingly, phenylephrine treatment decreased the lysosomal degradation of SWAP70 by disrupting the interaction of SWAP70 with granulin precursor. In vitro and in vivo experiments revealed that Swap70 knockdown/knockout accelerated the progression of pathological cardiac hypertrophy, while Swap70 overexpression restrained the cardiomyocyte hypertrophy. SWAP70 restrained the binding of transforming growth factor β‐activated kinase 1 (TAK1) and TAK1 binding protein 1, thus blocking the phosphorylation of TAK1 and downstream c‐Jun N‐terminal kinase/P38 signaling. TAK1 interacted with the N‐terminals (1–192) of SWAP70. Swap70 (193–585) overexpression failed to inhibit cardiac hypertrophy when the TAK1–SWAP70 interaction was disrupted. Either inhibiting the phosphorylation or suppressing the expression of TAK1 rescued the exaggerated cardiac hypertrophy induced by Swap70 knockdown. CONCLUSIONS: SWAP70 suppressed the progression of cardiac hypertrophy, possibly by inhibiting the mitogen‐activated protein kinases signaling pathway in a TAK1‐dependent manner, and lysosomes are involved in the regulation of SWAP70 expression level.
format Online
Article
Text
id pubmed-10122912
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101229122023-04-24 SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner Qian, Qiaofeng Hu, Fengjiao Yu, Wenjun Leng, Dewen Li, Yang Shi, Hongjie Deng, Dawei Ding, Kehan Liang, Chuan Liu, Jinping J Am Heart Assoc Original Research BACKGROUND: Pathological cardiac hypertrophy is regarded as a critical precursor and independent risk factor of heart failure, and its inhibition prevents the progression of heart failure. Switch‐associated protein 70 (SWAP70) is confirmed important in immunoregulation, cell maturation, and cell transformation. However, its role in pathological cardiac hypertrophy remains unclear. METHODS AND RESULTS: The effects of SWAP70 on pathological cardiac hypertrophy were investigated in Swap70 knockout mice and Swap70 overexpression/knockdown cardiomyocytes. Bioinformatic analysis combined with multiple molecular biological methodologies were adopted to elucidate the mechanisms underlying the effects of SWAP70 on pathological cardiac hypertrophy. Results showed that SWAP70 protein levels were significantly increased in failing human heart tissues, experimental transverse aortic constriction–induced mouse hypertrophic hearts, and phenylephrine‐stimulated isolated primary cardiomyocytes. Intriguingly, phenylephrine treatment decreased the lysosomal degradation of SWAP70 by disrupting the interaction of SWAP70 with granulin precursor. In vitro and in vivo experiments revealed that Swap70 knockdown/knockout accelerated the progression of pathological cardiac hypertrophy, while Swap70 overexpression restrained the cardiomyocyte hypertrophy. SWAP70 restrained the binding of transforming growth factor β‐activated kinase 1 (TAK1) and TAK1 binding protein 1, thus blocking the phosphorylation of TAK1 and downstream c‐Jun N‐terminal kinase/P38 signaling. TAK1 interacted with the N‐terminals (1–192) of SWAP70. Swap70 (193–585) overexpression failed to inhibit cardiac hypertrophy when the TAK1–SWAP70 interaction was disrupted. Either inhibiting the phosphorylation or suppressing the expression of TAK1 rescued the exaggerated cardiac hypertrophy induced by Swap70 knockdown. CONCLUSIONS: SWAP70 suppressed the progression of cardiac hypertrophy, possibly by inhibiting the mitogen‐activated protein kinases signaling pathway in a TAK1‐dependent manner, and lysosomes are involved in the regulation of SWAP70 expression level. John Wiley and Sons Inc. 2023-03-28 /pmc/articles/PMC10122912/ /pubmed/36974751 http://dx.doi.org/10.1161/JAHA.122.028628 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Qian, Qiaofeng
Hu, Fengjiao
Yu, Wenjun
Leng, Dewen
Li, Yang
Shi, Hongjie
Deng, Dawei
Ding, Kehan
Liang, Chuan
Liu, Jinping
SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
title SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
title_full SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
title_fullStr SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
title_full_unstemmed SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
title_short SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
title_sort swap70 overexpression protects against pathological cardiac hypertrophy in a tak1‐dependent manner
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122912/
https://www.ncbi.nlm.nih.gov/pubmed/36974751
http://dx.doi.org/10.1161/JAHA.122.028628
work_keys_str_mv AT qianqiaofeng swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT hufengjiao swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT yuwenjun swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT lengdewen swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT liyang swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT shihongjie swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT dengdawei swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT dingkehan swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT liangchuan swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner
AT liujinping swap70overexpressionprotectsagainstpathologicalcardiachypertrophyinatak1dependentmanner